A shortage listing ends. 4 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Shortage listings
Page 7 of 13 of this archive, newest first.
The lowest effective dose is a real concept with almost no data behind it
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Side effects, cost, supply, target: four reasons with four trajectories
The trials studied planned withdrawal. Almost nobody stops that way.
A shortage listing ends. 16 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 29-day notice: how a compounding wind-down works in Norway
The document is four pages. Three of them are about dates.
A shortage listing ends. 10 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
A shortage listing ends. 4 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
A shortage listing ends. 5 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 8-day notice: how a compounding wind-down works in India
The document is four pages. Three of them are about dates.
What the pharmacokinetics permit and what they cannot tell you
A great deal of practice has grown up around intermittent schedules. The randomised evidence for any of them is, as far as the Journal can establish, nil.
The 22-day notice: how a compounding wind-down works in Ireland
The document is four pages. Three of them are about dates.
What STEP 8 tells us about maintenance, and what it does not
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The 28-day notice: how a compounding wind-down works in Germany
The document is four pages. Three of them are about dates.
A design note on withdrawal trials, and why the run-in matters
The regain trajectories, arm by arm, with the estimands named.
A year after stopping: what the trials found at the far end
The variance around the mean regain trajectory is large and unexplained, exactly as it is for the weight loss.
A shortage listing ends. 12 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The supply gap as a clinical event
The trials studied planned withdrawal. Almost nobody stops that way.
A shortage listing ends. 16 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
A shortage listing ends. 9 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
A shortage listing ends. 3 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.